CVR Medical Corp

wie heute die Börsen von Kanada und der USA reagieren werden.  

Ohne News der anstieg oder habe ich was verpaßt ?  

die Studie begann Anfangs Jahr und im Dezember sollen die Resultate kommen.
Ich denke, die Insider wissen nun schon annähernd Bescheid wie die Resultate aussehen werden. s.#25  

 

wird vielleicht doch ein Hit :-)
Es wir von eine Revolution gesprochen
. The report on CVR Medical titled "Revolutionizing the Vascular Diagnostics Market"

hier der Report;
http://cvrmed.com/wp-content/uploads/2017/09/...roup-Sept-11-2017.pdf

 

Lang genug halte ich sie ja auch wenn man mir riet sie zu verkaufen. Grins  

Today, we need to talk about a new business profile, CVR MEDICAL CORP COM NPV (OTCMKTS:CRRVF), a healthcare company. CRRVF released a report about the positive results of the clinical trials for its “Carotid Stenotic Scan (CSS)” device at Thomas Jefferson University, which made the share price jump astonishingly in September.
CRRVF Logo (Source: cvrmed.com/)

CVR Medical Corp. Logo

The share price commenced, in the month of September, trading at the level of $0.25 and jumped to touch the level of almost $0.40 in only a few days. Have a look at the share price action before we provide more details that explain the share price move:
One year stock chart for CVR MEDICAL CORP COM NPV OTCMKTS:CRRVF

Business

CVR Medical Corp. was founded on December 10, 1980 in Canada. It operates through a joint venture agreement with CVR Global, Inc., which was incorporated under Michigan law in 2007 and operates in the medical industry. It is focused on the commercialization of a proprietary sub-sonic, infrasonic, and low frequency sound wave analysis technology. The company headquarters is in North Vancouver, British Columbia.

What’s the business model?

CRRVF is developing a medical device called Carotid Stenotic Scan, which “listens to sound waves produced by the flow of blood within the carotid arteries, analyzing the data to provide the clinician with a report detailing the level of blockage present.”

How does the company assess sound waves?

It owns proprietary sensors developed in house and under a Cooperative Research and Development Agreement with the Army Research Lab:

  “These proprietary sensors were developed to enhance the acoustic characteristics of the blood flow under analysis. The low frequency sound patterns are then analyzed by CVR’s proprietary technology. The Device is designed to be a non-invasive, costeffective tool to assess the direct risk factor for arterial disease. Further, the Device is cost effective when compared to other arterial assessment modalities within the healthcare field which requires operation by trained experts and interpretation by medical specialists.” Source

What’s the size of the market?

The device is intended for identifying the probability of suffering strokes. According to the World Health Organization, the stroke accounts for 6.2 million deaths annually. Additionally, as per the Centers for Disease Control and Prevention, stroke leads to 1 out of every 20 deaths, costing roughly $33 billion each year in the U.S. That’s not all. The global stroke diagnostics market was worth US$21.5 billion in 2015 and is expected to be US$31 billion by 2021.

Hence, the company seems to be delivering a medical device, which will not be sold only in a large market, the amount of customers seem to be increasing at a large pace. This fact should make the company worth much more.

Recent Developments

The most significant seemed to be the news released on September 7, 2017. The company noted a summarized report on data from the tertiary clinical trials for the “Carotid Stenotic Scan” device at Thomas Jefferson University. The company said that the report written by Dr. Phillip J. Bendick, PhD, confirms the device’s value and efficiency.

According to the this doctor, “nearly all of the tested patients that had carotid artery stenosis were identified without an overread.” From a financial perspective, the most interesting were the words of CVR CEO, Peter Bakema, who said the following about the new developments and the FDA:

  “Internally, in discussions with our engineering and scientific development teams, indications are that we expect the device to improve markedly above the 85% sensitivity level. This, coupled with the expansion of trials for a larger sample size, continues to put us in position for a successful submission to the FDA.” Source

Furthermore, another report was released some days later. RB Milestone Group, LLC, released “Revolutionizing the Vascular Diagnostics Market“, which we could find on the company website. We had a look at the report and considered interesting noting the amount of revenues that are expected:

  “CVR Medical has projected the net income in year 1 of sales to be $3.9 million by adopting an extremely conservative view of how the product will be received in the market. The Company has estimated the sale price of the CSS device to be $49,000. At this price, the Company expects a profit of about $31,480 per device” Source

In our opinion, if the company obtains this amount of revenues, the share price should jump much more (note that it did when the report was released). We will be following the next company’s announcements for this reason. We encourage readers to do the same.

Finally, it was also interesting to see that new executives are interested in joining the company. On September 14, 2017, Mr. Alan Langston was elected as Vice President of Sales and Marketing. According to the press release, he will be responsible for market entry strategies for the company’s Carotid Stenotic Scan (CSS) device. He has expertise in working for big corporations, such as Kontron America, Panasonic, Arrow Electronics, Avnet, GE, Siemens, and Philips. We believe that the election of a new executive was a good move.

Conclusion

Currently trading with a market cap of $20 million, CRRVF is an exciting story among small caps. The news are not only good thing, rather we found a considerable amount of cash, no long term debt, and little liabilities in the financial accounts. We appreciate this fact, as the company seems to have a lot of gasoline to run.  

also ich habe mich mal hier durchgewurschtelt. Das klingt interessant!


CVR adds wireless system for carotid stenotic scan



2017-11-21 10:26 ET - News Release


Mr. Peter Bakema reports

CVR MEDICAL MEETS CRITICAL MILESTONE! DEPLOYS WIRELESS SYSTEM AT THOMAS JEFFERSON UNIVERSITY

CVR Medical Corp. has fully integrated the carotid stenotic scan wireless device into its late-stage, continuing clinical trials being conducted at Thomas Jefferson University. The wireless system is the key component of the novel device's efficient and user-friendly design. The wireless intellectual property in CVR's portfolio fortifies barrier to entry.

"We have now finalized the key milestone, by deploying the wireless version of the CSS at Thomas Jefferson University. The wireless version of the CSS has been three years in design, development, validation and now deployment," says CVR chief operating officer, Tony Robinson. "This is one of the many state-of-the-art advantages we've built into the device, and we believe it goes a long way in reducing cost, easing operation and streamlining entry into the marketplace." The clinician can easily incorporate this revolutionary technology into their office without the need of a certified technician.

To expedite Food and Drug Administration approval, CVR will add additional clinical sites for pivotal trials with the wireless device in anticipation of market launch in 2018.

About CVR Medical Corp.

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. The joint venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

We seek Safe Harbor.


Hier könnte demnächst interessant werden  

 

kommen jetzt im Dezember Ergebnisse, wann genau hab ich noch nicht herausgefunden. Werde  aber Kontakt aufnehmen um einige Infos zu erhalten.
Wie es aussieht hat man auch Kontakte nach China geknüpft um dort 2018 in den Markt zukommen.
Also klingt interessant ist meine Empfehlung für die Watchl.
Sobald neue Informtionen vorliegen und die Positiv ausfallen würde ich aufstocken.  

es wird ähnlich wie bei CHROMEDX abgehen plötzlich und unerwartet ;-))  

Was ist mit dem Kurs geschehen ? Haben viele umgeschichtet zu chromedx ?  

CVR Medical Meets Critical Milestone! Deploys Wireless System at Thomas Jefferson University

VANCOUVER, BC / ACCESSWIRE / November 21, 2017 / CVR Medical Corp. (TSX.V:CVM.V) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) announces the full integration of the “Carotid Stenotic Scan (CSS)” wireless device into its late stage, ongoing clinical trials being conducted at Thomas Jefferson University.  The wireless system is the key component of the novel device’s efficient and user-friendly design.  The wireless Intellectual Property in CVR’s portfolio fortifies barrier to entry.

“We have now finalized the key milestone, by deploying the wireless version of the CSS at Thomas Jefferson University.  The wireless version of the CSS has been 3 years in design, development, validation and now deployment” says CVR COO Tony Robinson.  “This is one of the many state-of-the-art advantages we’ve built into the device, and we believe it goes a long way in reducing cost, easing operation and streamlining entry into the marketplace.”  The clinician can easily incorporate this revolutionary technology into their office without the need of a certified technician.

To expedite FDA approval, CVR will add additional clinical sites for pivotal trials with the wireless device in anticipation of market launch in 2018.

For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com  

es bald richtig!! spannend werden.
 

CVR Medical, Canon Sign Manufacturing Agreement for Breakthrough Device

VANCOUVER, BC / ACCESSWIRE / January 2, 2018 / CVR Medical Corp. (TSX.V:CVM.V) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) announces the signing of a manufacturing agreement with Canon Virginia, Inc., a manufacturing, engineering and technical operation for Canon and a wholly owned subsidiary of Canon U.S.A. The agreement finalizes Canon Virginia’s status as primary manufacturer, assembler, and logistical authority for CVR’s “Carotid Stenotic Scan (CSS)” device.

CVR’s novel device, currently undergoing final phase trials at several world-renowned medical institutions, is positioned for imminent FDA submission and subsequent market launch targeted for H1 2018.

“As progress accelerates, this is a milestone which I value more than most,” CVR CEO Peter Bakema states. “Moving forward with Canon Virginia is truly the best possible outcome we planned for. Financially speaking, their breadth of in-house capabilities and supply-chain efficiencies will translate to tens of millions in short-term production and logistical cost savings. And furthermore, the Canon Virginia associations of quality, reliability and user-friendly design give the CSS immediate brand recognition that puts CVR on a trajectory to achieve our ultimate goal: change the cardiovascular healthcare landscape.”

For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com

Google Übersetzung:

CVR Medical, Canon Sign Manufacturing Agreement für bahnbrechendes Gerät

VANCOUVER, BC / ACCESSWIRE / 2. Januar 2018 / CVR Medical Corp. (TSX.V: CVM.V) ("CVR Medical") gibt die Unterzeichnung einer Produktionsvereinbarung mit Canon Virginia bekannt , Inc., ein Produktions-, Engineering- und technisches Unternehmen für Canon und eine hundertprozentige Tochtergesellschaft von Canon USA Der Vertrag schließt den Status von Canon Virginia als Primärhersteller, Monteur und logistische Autorität für das CVR-Gerät "Carotis Stenotic Scan (CSS)" ab.

CVRs neuartiges Gerät, das sich derzeit in Endphase-Studien an mehreren weltbekannten medizinischen Einrichtungen befindet, ist für die bevorstehende FDA-Einreichung und anschließende Markteinführung für H1 2018 ausgerichtet.

"Wenn sich der Fortschritt beschleunigt, ist dies ein Meilenstein, den ich mehr wertschätze als die meisten", sagt CVR-CEO Peter Bakema. "Mit Canon Virginia voranzukommen, ist wirklich das bestmögliche Ergebnis, das wir uns vorgenommen haben. Finanziell gesehen werden ihre internen Kapazitäten und die Effizienz der Lieferkette zu Einsparungen in Millionenhöhe bei kurzfristigen Produktions- und Logistikkosten führen. Darüber hinaus verleihen die Canon Virginia-Vereinigungen für Qualität, Zuverlässigkeit und benutzerfreundliches Design der CSS eine unmittelbare Markenerkennung, die CVR auf den Weg bringt, unser ultimatives Ziel zu erreichen: die kardiovaskuläre Gesundheitslandschaft zu verändern. "

Für weitere Informationen über die Organisation, Führung und aktuelle Nachrichten besuchen Sie bitte die neu lancierte Unternehmens-Website www.CVRMed.com
Google Übersetzer für Unternehmen:Translator ToolkitWebsite-Übersetzer
 

sind phänomenal. Zusammenarbeit mit Canon ist eine sichere Bank. Besser hätte ich es mir nicht erträumen lassen. Ganz klar wird cvr ein hiddenChamp 18' für mich  

auch investiert ! Hatte gedacht du hättest dich jetzt erst mit der Aktie auseinandergesetzt  

ich bin schon etwas länger dabei fred ^J^
 

immer wieder mal welche gekauft bei schwäche.. das aber jetzt so schnell bewegung reinkommt wow  

 

 

das es so still ist. Die nummer mit Canon ist schon eine ansage. Es steht hier nicht blockchain oder milliarden gewinn dahinter.. aber ne steife Sache kann das hier demnächst werden. Zulassung und Vermarktung in diesem Jahr, quasi ein Canon produkt das isn selbstläufer. Wenn hier Volmen reinkommt dann sollte das hier richtig schön Steil gehn. Hab mich hier seid Wochen sehr zurück gehalten. Aber nun bin ich nen FULLower..  

den wert der Atie ist schwer einzuschätzen oder ? Wenn das CSS nicht zu teuer ist könnte es nicht nur in Krankenhäusern sondern auch bei Praktischen Ärzten und Neurologen stehen.  

mal stark ausgehen Fred! Das system ist anscheinend weitbüberlegen und kann quasi sofort eingesetzt leben retten. Das Interesannte meiner Meinung nach ist, das man einen ganzen Vorsorgezweig darauf aufbauen kann. Schlag und Heranfälle stehen ganz oben auf der skala!  

Carotid Stenotic Scan (CSS)

$49,000

No Certified Tech RequiredDr. Fee:$100 / Estimated Reimbursement: $105 Per ScanNon-EmittingNon-InvasiveAccurate & Repeatable2 Minute Scan

Carotid Doppler Ultrasound

$250,000

Requires Radiological Assistant (Salary $75k-$100k)Reimbursement: $180-$400 Per ScanEmits High Energy Sound WaveNon-InvasiveAccuracy is User Dependent30-60 Minute Process

Magnetic Resonance Angiography (MRA)

$1-2,5M

Requires Radiological Assistant (Salary $75k-$100k)Reimbursement: $3,000 Per ScanEmits RadiationContrast Agent UsedAccuracy is User Dependent>60 Minute Process

Computed Tomography Angiography (CTA)

$1-2,5M

Requires Radiological Assistant (Salary $75k-$100k)Reimbursement: $500-$1,500 Per ScanEmits RadiationContrast Agent UsedAccuracy is User Dependent30-60 Minute Process